ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca has agreed to acquire the T-cell receptor (TCR) therapy company Neogene for $200 million on closing and up to $120 million in other payments. Many T-cell therapies involve getting a person’s T cells to recognize a protein on the surface of cancer cells; TCR therapies are able to recognize intracellular targets, the companies say, which could broaden their available targets. The firms say they aim to deliver cell therapies to people with solid tumors.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X